ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1301 • ACR Convergence 2023

    The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis

    Maryam Adas1, Sam Norton1, Andrew Cope1, Maya Buch2, James Galloway1 and Elena Nikiphorou1, 1King's College London, London, United Kingdom, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

    Background/Purpose: Psychosocial factors may interplay with biological factors to drive a refractory disease state in patients with inflammatory arthritis1. We aim to explore which socioeconomic,…
  • Abstract Number: 1317 • ACR Convergence 2023

    Discontinuation of Biological Disease Modifying Drugs Due to Adverse Drug Reactions in an Inception Rheumatoid Arthritis Cohort

    Zulema Rosales-Rosado1, Maria Rodriguez Laguna2, Cristina lajas Petisco2, Clara De Miguel2 and lydia Abasolo1, 1Hospital Clínico San Carlos, Madrid, Spain, 2Hospital Clinico San Carlos, Madrid, Spain

    Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the use of Disease Modifying Drugs (DMARD).…
  • Abstract Number: 1334 • ACR Convergence 2023

    Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses

    Marina Birck1, Luck Lukusa2, Michal Abrahamowicz3, Gilles Boire4, Denis Choquette5, Walter P. Maksymowych6 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2RI-MUHC, Montreal, QC, Canada, 3McGill University, Verdun, QC, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, 6University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
  • Abstract Number: 1363 • ACR Convergence 2023

    Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills

    Background/Purpose: Women develop RA 3 times more often than men, and several risk factors for RA are female specific. Prior studies demonstrate an association between…
  • Abstract Number: 1680 • ACR Convergence 2023

    What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?

    Rieke Alten1, Juan carlos Nieto-Gonzalez2, Peggy Jacques3, Carlomaurizio Montecucco4, Robert Moots5, Helga Radner6, Sebastian Heidenreich7, Chiara Whichello7, Nicolas Krucien7, Monia Zignani8, Harald Vonkeman9 and Katrien Van Beneden10, 1Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 2Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Department of Rheumatology and VIB Inflammation Research Center, University Hospital Ghent, Ghent, Belgium, 4Division of Rheumatology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 5Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, 6Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 7Patient-centred Research, Evidera Inc., London, United Kingdom, 8Medical Affairs, Galapagos GmbH, Basel, Switzerland, 9Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands, 10Medical Safety, Galapagos NV, Mechelen, Belgium

    Background/Purpose: Multiple RA therapies are available that differ in attributes such as mode of administration and benefit-risk profile. Challenging trade-offs are made during treatment selection…
  • Abstract Number: 1735 • ACR Convergence 2023

    An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry

    Christian Geier1, Haani Qudsi2, Jihad BenGabr1, Robert Winchester3 and Andras Perl4, 1SUNY Upstate Medical University, Syracuse, NY, 2Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, 3Columbia University, New York, NY, 4SUNY, Syracuse, NY

    Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
  • Abstract Number: 1751 • ACR Convergence 2023

    Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls

    Namit Kumar1, Xueer Chen2, Mary Ann Aure3, Andy Ishii4, Laura Martinez-Prat5, chelsea Bentow4, Jasmine Saini2, Michael Mahler4 and Laurence Menard2, 1Bristol Myers Squibb, San Diego, CA, 2Bristol Myers Squibb, Princeton, NJ, 3Werfen, Chula Vista, CA, 4Werfen, San Diego, CA, 5Werfen Autoimmunity, Sant Cugat del Vallès, Spain

    Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
  • Abstract Number: 1767 • ACR Convergence 2023

    TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation

    Farheen Sultan Shaikh1, Anil Singh1, Paul Panipinto2 and Salahuddin Ahmed1, 1Washington State University, Spokane, WA, 2Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA

    Background/Purpose: Tumor necrosis factor-alpha (TNF)-α is a proinflammatory cytokine in rheumatoid arthritis that transduces intracellular signal transduction pathways through specific receptors, TNF-R1, and TNF-R2. The…
  • Abstract Number: 1860 • ACR Convergence 2023

    Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis

    Alyssa Howren1, Eric Sayre2, J. Antonio Avina-Zubieta3, Joseph Puyat1, Deborah Da Costa4, Hui Xie5, Amit Gupta1 and Mary De Vera1, 1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Centre on Substance Use, Vancouver, BC, Canada, 3Arthritis Research Canada, Vancouver, BC, Canada, 4McGill University, Pointe-Claire, QC, Canada, 5Simon Fraser University, Richmond, BC, Canada

    Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…
  • Abstract Number: 1934 • ACR Convergence 2023

    Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis

    Stanley Cohen1, Shaun Bender2, Amy Shaberman3, Richard Vinisko3 and Dorothy McCabe3, 1University of Texas Southwestern, Dallas, TX, 2Alnylam Pharmaceuticals, Cambridge, MA, 3Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

    Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severe rheumatoid…
  • Abstract Number: 2105 • ACR Convergence 2023

    Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases

    Hiroaki Tanaka1, Yukinori Okada2, Shingo Nakayamada1, Yusuke Miyazaki3, Kyuto Sonehara4, Shinichi Namba5, Suguru Honda6, Yuya Shirai7, Kenichi Yamamoto5, Katsunori Ikari8, Masayoshi Harigai9, KOSHIRO SONOMOTO10 and Yoshiya Tanaka1, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, 3The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, 4University of Tokyo, Tokyo, Japan, 5Osaka University, Osaka, Japan, 6Tokyo Women's Medical University, Tokyo, Japan, 7Osaka University, Suita, Japan, 8Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 9Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 10University of Occupational and Environmental Health, Beppu, Japan

    Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
  • Abstract Number: 2121 • ACR Convergence 2023

    Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis

    Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan

    Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
  • Abstract Number: 2137 • ACR Convergence 2023

    Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics

    Jeffrey Curtis1, Fenglong Xie1, Yuji Su2, Patrick Stewart3 and Amy S. Mudano1, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham and Illumination Health, Birmingham, AL, 3Illumination Health, Birmingham, AL

    Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…
  • Abstract Number: 2153 • ACR Convergence 2023

    Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis

    György Kerekes1, Monika Czókolyová1, Attila Hamar1, Anita Pusztai1, Gábor Tajti1, Mónika Katkó1, Edit Végh1, Zsófia Pethő1, Nóra Bodnár1, Ágnes Horváth1, Boglárka Soós1, Szilvia Szamosi1, Zsolt Hascsi1, Mariann Harangi1, Katalin Hodosi1, György Panyi1, Tamas Seres2, Gabriella Szücs1 and Zoltán Szekanecz1, 1University of Debrecen, Faculty of Medicine, Debrecen, Hungary, 2University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Cardiovascular (CV) morbidity, mortality and perpetuated synovial angiogenesis have been associated with rheumatoid arthritis (RA). In our study we evaluated angiogenic factors in relation…
  • Abstract Number: 2170 • ACR Convergence 2023

    Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study

    Ho SO1, Tommy LAM2, Huan MENG3, Steven LAM3 and Lai-Shan Tam4, 1The Chinese University of Hong Kong, Hong Kong, China, 2Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong, 3The Chinese University of Hong Kong, Hong Kong, Hong Kong, 4The Chinese University of Hong Kong, New Territories, China

    Background/Purpose: Rheumatoid arthritis (RA) and systemic glucocorticoid (GC) use are associated with increased risk of cardiovascular disease. The latest RA management recommendations from the American…
  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology